Kingston, Belinda http://orcid.org/0000-0002-4921-4638
Cutts, Rosalind J.
Bye, Hannah
Beaney, Matthew
Walsh-Crestani, Giselle
Hrebien, Sarah
Swift, Claire
Kilburn, Lucy S. http://orcid.org/0000-0002-1987-7545
Kernaghan, Sarah
Moretti, Laura http://orcid.org/0000-0003-0488-0140
Wilkinson, Katie
Wardley, Andrew M.
Macpherson, Iain R. http://orcid.org/0000-0003-4295-8885
Baird, Richard D. http://orcid.org/0000-0001-7071-6483
Roylance, Rebecca
Reis-Filho, Jorge S. http://orcid.org/0000-0003-2969-3173
Hubank, Michael
Faull, Iris http://orcid.org/0000-0001-6005-077X
Banks, Kimberly C. http://orcid.org/0000-0002-1290-3114
Lanman, Richard B. http://orcid.org/0000-0001-8122-4329
Garcia-Murillas, Isaac http://orcid.org/0000-0001-8183-7969
Bliss, Judith M.
Ring, Alistair http://orcid.org/0000-0003-1230-2973
Turner, Nicholas C.
Funding for this research was provided by:
Cancer Research UK (A25161)
Breast Cancer Now (CTR-Q5-Y1, CTR-Q5-Y1)
Article History
Received: 29 June 2020
Accepted: 16 March 2021
First Online: 23 April 2021
Change Date: 16 July 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-24791-5
Competing interests
: N.C.T., AR, JMB., L.S.K., C.S., L.M., S.K., K.W., S.M., H.B., M.H., B.K, I.G.M., M.B., G.W.-C., S.H. and R.C. report grants from Cancer Research UK, grants and non-financial support in the form of study drug provision from AstraZeneca and Puma Biotechnology and non-financial support in the form of ctDNA sequencing from Guardant Health and provision of reagents from BioRad during the conduct of the study. N.C.T. also reports grants and personal fees from AstraZeneca, Pfizer, and Roche/Genentech, personal fees from Bristol-Myers Squibb, Lilly, MSD, Novartis, Bicycle Theraputics, Taiiho, Zeno Pharmaceuticals and Repare Therapeutics and grants from BioRad, Clovis, Merck Sharpe and Dohme, and Guardant Health outside the submitted work. B.K. also reports personal fees from Guardant Health outside the submitted work. A.M.W. reports personal fees from Roche, personal fees and other support from Novartis, Pfizer, Lilly, Daiichi-Sankyo, MSD, AstraZeneca, Athenex and other support from Seattle Genetics, Andrew Wardley Ltd, Manchester Cancer Academy and Outreach Research and Innovation Group Limited outside the submitted work. I.R.M. reports personal fees and non-financial support from Roche Products UK Ltd, Eli Lilly and Eisai and personal fees from Novartis, Pfizer, Daichi Sankyo, Genomic Health, Pierre Fabre and MSD outside the submitted work. R.D.B. reports grants from AstraZeneca and Roche/Genentech outside the submitted work. R.R. reports personal fees from Novartis, Eli-Lilly and Pfizer, personal fees and non-financial support from Daiichi Sankyo and G1Therapeutics and non-financial support from Roche and AstraZeneca outside the submitted work. H.B. also reports personal fees from AstraZeneca outside of the submitted work. M.H. also reports also reports personal fees from Bristol Myers Squibb, Boehringer Ingelheim, Roche Diagnostics and Eli Lilly during the conduct of the study. J.M.B. also reports grants and non-financial support from AstraZeneca, Novartis, Janssen-Cilag, Merck Sharpe & Dohme, Pfizer, Roche, and Clovis Oncology and grants from Medivation outside the submitted work. A.R. also reports personal fees from Roche Products Limited, Pfizer, Novartis, Lilly and M.S.D. outside the submitted work. J.S.R.-F. is a consultant of Goldman Sachs and REPARE Therapeutics, a member of the scientific advisory board of Volition Rx and Paige.AI, and an ad hoc member of the scientific advisory board of Ventana Medical Systems, Roche Tissue Diagnostics, Genentech, Novartis and InVicro. I.F., K.S.B. and R.B.L. are employees with stock ownership in Guardant Health, Inc.